Androgen deprivation therapy, such as Relugolix, may prolong the QT/QTc interval.
- Trade Name: Orgovyx (Myovant Sciences)
- Indications: Treatment of adult patients with advanced prostate cancer.
- Class: Anti-prostate cancer agent, Gonadotropin-releasing hormone (GnRH) antagonist
- Half-life: 25 hours
- FDA Approval Date: 12/18/2020
- Clinically important, potentially hazardous interactions with:
CYP3A inducers, Erythromycin, P-gp inhibitors, Rifampin - Pregnancy: Relugolix can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 09/25/2026
